Liver Disease Models and Efficacy Services
The liver is an essential hub for material and energy metabolic processes. The impact of alcohol, drugs, and toxic chemicals usually produces acute or chronic liver injury, which can progress to liver fibrosis, cirrhosis, or liver cancer if not appropriately managed. Consequently, experimental animal models of liver disease are essential for investigating the pathophysiology of liver disease and screening therapeutic medicines.GemPharmatech offers liver fibrosis models, metabolic dysfunction-associated steatohepatitis models, and related-efficacy evaluation services.
- Liver Fibrosis Models
-
Liver fibrosis refers to a pathological process marked by the excessive deposition of extracellular matrix in the liver and serves as an intermediate in the progression of several liver disorders. Selecting appropriate animal models of liver fibrosis is imperative to understanding the etiology of liver fibrosis as well as selecting the most efficient screening method for anti-liver fibrosis medicines. GemPharmatech established drug-induced liver fibrosis models, which can be utilized to examine the therapeutic effects of medications on liver fibrosis.
- CCl4-induced liver fibrosis model
- Metabolic dysfunction-associated steatohepatitis (MASH) Models
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a disorder in which a substantial quantity of fat accumulates in the liver of non-alcoholic individuals. Metabolic dysfunction-associated steatohepatitis (MASH) is a severe form of MASLD characterized by fatty liver lesions, inflammation, vacuolation, and fibrosis in the liver lobules. Preclinical animal models are crucial to develop novel anti-MASH medications, and GemPharmatech has created several dietary or mutation-induced MASH mice models for preclinical efficacy testing.
- HFD+CCl4-induced MASH models
- HFD-induced BKS-db MASH models
- HFD-induced C57BL/60Alms 1-del MASH models
- Other MASH models
- Liver disease-related target humanized mouse models